Antimicrobials
Voriconazole

Voriconazole

Restricted

Low
N/A

Spectrum of Activity

General Information

Candida infections both mucocutaneous and invasive - i.e. Candidemia

Antifungal prophylaxis in immunocompromised

Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (discuss with ID)

Monitor QTc interval in patients at elevated risk

Monitor hepatic profile

  • QTc prolongation
  • Hepatic enzyme abnormalities
  • Rash - up to 20%
  • GI upset
  • Visual disturbances commonly associated with treatment, usually reversible with duration of use < 28 days.
  • Many via CYP450- suggest review interactions with pharmacist.
  • Risk when combining with other QTc prolonging agents

Antimicrobial class: Triazole antifungal, second generation

Average serum half life: Variable and dose dependent.

Route of Elimination: Urine (<2% as unchanged drug)